Balance Ophthalmics announced that the FDA has granted 510(k) clearance for a wireless-enabled, next-generation version of the FSYX Ocular Pressure Adjusting Pump (OPAP).

The clearance builds on the company’s previously granted De Novo classification for the FSYX platform, which was the first device specifically designed to reduce nocturnal IOP in glaucoma patients. The updated system introduces wireless communication capabilities, allowing eye care providers to access real-world patient usage data from at-home therapy.

FSYX (pronounced “physics”) remains the first and only non-pharmacological, non-surgical treatment designed to lower IOP during sleep in patients with glaucoma. The prescription-only system includes a compact pump connected to pressure-modulating goggles worn overnight to target a critical period when eye pressure often peaks and conventional therapies may provide less protection.

According to Balance Ophthalmics, FSYX demonstrated a 39% mean reduction in nighttime IOP across 12 clinical studies involving more than 600 eyes, with no device-related serious adverse events reported. The therapy is designed to complement existing glaucoma treatments, including medications and prior surgical interventions.

The newly cleared wireless functionality enables objective therapy adherence data to be transmitted directly to prescribing practices, offering clinicians greater visibility into patient engagement and treatment consistency.

“Many glaucoma patients progress at night when IOP runs highest and current therapies are least effective,” said Thomas W. Samuelson, MD, founding partner and attending surgeon at Minnesota Eye Consultants. “The OPAP is the first device designed to protect them during that window. The new wireless capability helps us detect, patient by patient, whether they’re actually receiving that protection while resting comfortably in their own home.”

Seph Jensen, CEO of Balance Ophthalmics, said the latest clearance represents a significant evolution of the company’s platform.

“Receiving 510(k) clearance for our next-generation FSYX OPAP builds directly on the foundation established with our De Novo classification,” Mr. Jensen said. “Wireless communication transforms the device into a connected clinical tool, giving practices insight into patient behavior at home. We are proud to bring this capability to glaucoma patients and the practices that care for them.”

Balance Ophthalmics said the new wireless FSYX OPAP system is expected to become available to eye care practices beginning in the fourth quarter of 2026.